When: $1,020-$1,040 flush

Then: Add to position

When: >$1,300 on >4M volume breakout

Then: Add to position

HOLD core position with 10-15% trim on rallies; reject tactical short entirely

• Trimming 10-15% on rallies into 1,200-1,250 is reasonable gain-harvesting after 81% move off 52-week low; reject 20-30% trim as too aggressive
• Initiating tactical shorts on stock with beta of 0.506 with rising 200 SMA at 1,060.38 is directional speculation, not risk management
• Technical deterioration (RSI 41, MACD histogram flip from plus 21.81 to minus 9.62) represents healthy intermediate correction, not structural breakdown
• 200 SMA at 1,060.38 rising represents institutional cost basis floor and rebalancing flows, not just chart line
• LLY fundamentals exceptional: 54.2% operating margins, 47.7% YoY revenue growth, $11B TTM FCF, 102% ROE
• Merida acquisition disciplined: 13 deals in 2026, intangibles jump to $18.1B from $7.4B, $8.75B deployed funded by $11.58B net debt leaving $2.8B incremental cash cushion
• Supply-constrained company building inventory ($11B to $16.8B) and PP&E ($20.5B to $29.3B) ahead of demand normalization; $14.5B annual capex confirms capacity investment thesis
• Novo Nordisk down 51.9% over three years reflects Novo's poor execution, not GLP-1 market weakness; LLY is gaining share
• Africa Mounjaro launch at 1.25% of quarterly sales is strategic footprint play establishing regulatory infrastructure and distribution relationships
• Trump drug pricing expansion to 26 companies carries industry-wide risk but LLY has not been named in three waves of pricing agreements; different patient population elasticity profile
• Polymarket 3% probability on Retatrutide 2026 approval means no surprise downside; market already pricing it as unlikely 2026 catalyst
• Amgen MariTide targets different patient profile; Pfizer berobeptide targets 2028; Superluminal Medicines Phase 1 is a decade away from commercial impact
• Absence of Reddit retail chatter reflects institutional accumulation phase, not demand absence; healthier ownership structure
• Wait-for-1060 reload thesis rejected: perfect entry timing is speculation, not risk management

→ vs aggressive: Conflates position trimming (10-15%) with tactical shorts (1-2% of portfolio); these are fundamentally different risk management decisions

→ vs aggressive: Treats intermediate correction as structural breakdown; technical analyst explicitly distinguished between the two

→ vs aggressive: Uses lagging MACD indicator to justify leading directional bet; momentum indicator tells what already happened, not where price goes

→ vs aggressive: Misreads Merida acquisition as balance sheet impairment; intangibles jump reflects acquisition accounting, not economic deterioration

→ vs aggressive: Dismissed Africa launch as immaterial strategic beachhead; 1.25% today becomes 5% in five years if GLP-1 emerging markets trajectory holds

→ vs aggressive: Overstates competitive timeline: Amgen targets different patient profile, Pfizer targets 2028, Superluminal is Phase 1 decade away

→ vs aggressive: Treats 3% Polymarket Retatrutide probability as bearish signal when it actually means no surprise downside risk

→ vs aggressive: Misreads inventory build in isolation; PP&E growth to $29.3B confirms capacity expansion consistent with supply-constrained thesis

→ vs aggressive: Interprets rising 200 SMA as destination for downside rather than strong support level historically holding during corrections

→ vs aggressive: Reads Reddit silence as bearish when institutional accumulation phase explains absence of retail chatter

Trim 15-20 percent on rallies into 1200-1250 zone; hold remaining 80-85 percent; do not initiate tactical shorts under any circumstances; reassess if stock breaks below 1125 and 200 SMA fails to hold

• Technical setup is short-term weak but long-term intact; currently in 'no-man's-land' where neither signal has won
• Valuation stretched at 38x trailing earnings and 24x forward earnings with PEG of 1.12, but fundamentally exceptional business
• Macro environment moderately negative for multiple but not catastrophic; LLY misclassified within defensive rotation
• GLP-1 competition won't meaningfully impact 2026 numbers; MariTide earlier-stage, Pfizer's berobenatide is 2028, Superluminal is Phase 1
• M&A is positive for long-term story but near-term overhang for multiple with debt-to-equity at 162 percent and 13 deals in a year
• Trump drug pricing is structural overhang likely to compress multiples over next 4-8 quarters but not imminent catalyst
• Tactical shorting rejected due to wrong asymmetry with beta of 0.506; short position bleeds slowly in adverse scenarios
• 200 SMA support at 1060 is real and rising but not a permanent floor guaranteed to hold

→ vs aggressive: Tactical short proposal is the weakest part of their case; shorting low-beta high-quality name with rising 200 SMA support and multiple uncatalysts is wrong asymmetry

→ vs aggressive: Competitive landscape argument is weakest part of their case; treating GLP-1 competition as going to meaningfully impact 2026 numbers when MariTide is earlier-stage, Pfizer is 2028, and Superluminal is Phase 1

→ vs aggressive: Blurring the distinction between trimming and exiting; trim is not the same thing as exiting

→ vs conservative: 200 SMA at 1060 is not a permanent floor guaranteed to hold; when it fails to hold, it fails fast

→ vs conservative: Trim recommendation of 10-15 percent is too cautious given technical setup, valuation, and macro environment together; 15-20 percent is more appropriate

→ vs conservative: 54 percent operating margins and 47 percent revenue growth don't immunize stock from multiple compression